BiomX Inc (PHGE)
0.3839
-0.02
(-5.91%)
USD |
NYAM |
May 03, 16:00
BiomX SG&A Expense (Quarterly): 2.597M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 2.597M |
September 30, 2023 | 2.154M |
June 30, 2023 | 2.255M |
March 31, 2023 | 1.644M |
December 31, 2022 | 1.985M |
September 30, 2022 | 2.633M |
June 30, 2022 | 2.361M |
March 31, 2022 | 2.477M |
Date | Value |
---|---|
December 31, 2021 | 2.831M |
September 30, 2021 | 2.845M |
June 30, 2021 | 3.098M |
March 31, 2021 | 2.493M |
December 31, 2020 | 2.574M |
September 30, 2020 | 2.394M |
June 30, 2020 | 2.297M |
March 31, 2020 | 2.058M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.644M
Minimum
Mar 2023
3.098M
Maximum
Jun 2021
2.418M
Average
2.436M
Median
SG&A Expense (Quarterly) Benchmarks
Taro Pharmaceutical Industries Ltd | 50.41M |
InspireMD Inc | 4.278M |
Alpha Tau Medical Ltd | 2.453M |
Pluri Inc | 2.354M |
Holdco Nuvo Group DG Ltd | -- |